Portal de Periódicos da CAPES

Classification of antituberculosis drugs: a new proposal based on the most recent evidence

2015; European Respiratory Society; Volume: 46; Issue: 4 Linguagem: Inglês

10.1183/13993003.00432-2015

1399-3003

José A. Caminero, Anna Scardigli,

Mycobacterium research and diagnosis

Multidrug-resistant (MDR) tuberculosis (TB) (resistance to at least isoniazid and rifampicin), with >480 000 cases in 2013, 10% of them being affected by extensively drug-resistant (XDR)-TB (MDR-TB with additional resistance to any fluoroquinolone, and to injectable second-line drugs (SLDs) (capreomycin, kanamycin or amikacin)), continues to represent a real threat to TB control [1–4]. In some high MDR-TB burden countries, the prevalence of MDR-TB among new cases exceeds 20% and among retreatment cases, reaches almost 50% [1, 5]. The classification of the anti-TB drugs should probably be modified to optimise the use old and new compounds The authors wish to thank R. Centis and L. D'Ambrosio (WHO Collaborating Centre for TB and Lung Disease, Tradate, Italy) for their editorial and technical support. The authors alone are responsible for the views expressed in this publication and they do not necessarily represent the decisions or policies of their institutions.